Cognitive Claims Stir Senators To Question FDA Supplement Regulation
This article was originally published in The Tan Sheet
Executive Summary
Senator McCaskill says FDA might “lack a systematic approach to preventing adulterated, mislabeled and fraudulent products from entering the market.” She and Senator Susan Collins ask FDA for a “detailed description” of the agency’s evaluation of medical and nutritional claims for supplements on the market.”